SL: Data curation, Investigation, Resources, Writing original draft
Avoid: All GLP-1 patches until Phase 3 clinical trials demonstrate their efficacy, which is not expected until 2030 or later, when microneedle technology may enable effective transdermal delivery of medications like semaglutide
We would like to thank all authors who provided information on the radiosensitivity of osteosarcoma and its related fields
Following it consistently is what separates people who get results from people who do not
For further information: DOI:10.1001/jamainternmed.2022.0338 Keywords: GLP-1 RA, Glucagon-like peptide-1 receptor agonists, biliary disease, Gallbladder disease, higher doses, Longer duration of GLP-1 RA, cholelithiasis, cholecystitis, GRADE framework, biliary cancer, JAMA Internal Medicine
Schoffelen PF, Westerterp KR, Saris WH, Ten HF